MELK-T1 is a potent and selective inhibitor of MELK (Maternal Embryonic Leucine Zipper Kinase), primarily utilized in biomedical research, particularly in the study of cancer biology. MELK is often overexpressed in various types of cancer, and MELK-T1 plays a significant role in understanding the mechanisms of cell proliferation and survival by inhibiting this kinase in cancer cells. Researchers use MELK-T1 to investigate MELK as a therapeutic target, aiming to disrupt the growth and survival of cancer cells, which could lead to the development of novel anticancer therapies. Additionally, MELK-T1 is studied for its involvement in stem cell regulation and potential implications in regenerative medicine. Its application extends to drug discovery, where it is used to screen and develop inhibitors effective in clinical settings for treating cancer and other diseases associated with abnormal cell growth, such as certain neurological and genetic disorders. Studies also suggest it may enhance the efficacy of chemotherapy by reducing cancer cell spread.